Dare Bioscience, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Dare Bioscience (market cap ~$21.3M) launched Flora Sync LF5 in July 2026, generating initial revenue of $0.187M in Q2. DARE to PLAY Sildenafil Cream is expected to begin prescription dispensing and revenue in Q3 2026, with prescriptions already being accepted. The company reported Q2 net loss of $2.98M (vs. $4.02M in Q2 2025), cash of $12.6M as of June 30, 2026, and received a $1.0M second tranche from NIAID for DARE-HPV program, bringing total NIAID award to $2.0M.
Why this rating
First direct commercialization and revenue inflection represent strategic inflection point for pre-revenue biotech. Combined with $1M NIH grant and positive pipeline data, materially advances near-term cash runway relative to company size, though absolute revenue remains modest and $12.6M cash creates 2-year pressure.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.